ClinicalTrials.gg
RecruitingNCT05900401Updated Sep 28, 2026

Delayed Tolerance Through Mixed Chimerism

A Phase 1/2 interventional study of Bone Marrow Transplant and Peripheral Blood Stem Cell Collection in Kidney Failure, Kidney Transplant; Complications and Chimera, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Massachusetts General Hospital · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Sep 28, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing cyclophosphamide in Renal Insufficiency — 3 open to participants now, 3 under way, none of them phase 3. Cyclophosphamide · Renal Insufficiency.

Planned enrollment
7th of 10
20 · median 41
Started
2023
the only one that year
Phase 1/2
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
2 of 10
Massachusetts General Hospital

Among the 10 studies testing cyclophosphamide in Renal Insufficiency, this one is the 7th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 1/2, and was the 9th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

3 of the 10 studies testing cyclophosphamide in Renal Insufficiency are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cyclophosphamide in Renal Insufficiency, or all of them as a file.
02

Study summary

This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system

Read the detailed description

Recipients of previous living donor (LD) or deceased donor (DD) kidney transplants that were maintained on conventional immunosuppression (I.S.), will receive a conditioning regimen that includes rituximab on study day -6, fludarabine 15 mg/m2/day on days -5 to -3 (3 doses), Cyclophosphamide (30 mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1. Donor hematopoetic stem cells (HSCs) will be infused on study day 0. Methylprednisolone 250mg/day will be started on day 0 and tapered off by day 20 (Fig. 2). Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 12 months following HSC Transplant. The recipients will undergo renal allograft biopsy at 6 months after HSCT. If the I.S. withdrawal criteria are met, I.S. will be slowly tapered off by 9-12 months

03

Conditions studied

  • Kidney Failure
  • Kidney Transplant; Complications
  • Chimera

Browse trials for

Keywords

  • Tolerance
  • Transplant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Recipient Inclusion Criteria

  1. Male or female 18-65 years of age.
  2. Kidney transplant recipients from either LD or DD, with cryo-preserved HSCs available, good renal function (>60 ml/min/1.73m2), normal current allograft , and no history of documented rejection episodes.
  3. First or second renal transplant.
  4. Use of FDA-approved methods of (those with less than a 3% failure rate) by all recipients from the time that study treatment begins until 104 weeks (24 months) after renal transplantation. (For further information on FDA- approved methods of contraception, see https://www.fda.gov/media/150299/download
  5. Ability to understand and provide .
  6. Negative COVID-19 test during screening and two days prior to HSC transplantation ().

Deceased Donor (DD)

  1. Male or female 18-70 years of age.
  2. Consent to donate vertebral bones is obtained from the donor family.
  3. HSCs are successfully cryopreserved and saved >2X106/kg (CD34+ cells) of the recipient.
  4. Acceptable laboratory parameters (hematology in normal or near-normal range. Liver function \<2 times the , and normal creatinine)
  5. Negative for viral infection with HbsAg, , , or HTLV-1
  6. Negative COVID-19 test at the time of HSC procurement.

Living Donor (LD)

  1. Willingness to provide HSCs by leukapheresis or bone marrow aspiration.
  2. Negative serologic pregnancy test for females of
  3. Good general health as per conventional evaluation for kidney donation.
  4. Acceptable laboratory parameters (hematology in normal or near normal range. Liver function \<2 times the upper limit of normal, and normal creatinine)
  5. Negative for viral infection with HbsAg, HIV, HCV, or HTLV-1.
  6. Cardiac/pulmonary function within normal limits (CXR, ).
  7. Ability to understand and provide informed consent.
  8. Meets standard institutional criteria for PBSC collection.
  9. Negative COVID-19 test during screening and two days prior to PBSC collection.

Recipient Exclusion Criteria

  1. ABO blood group-incompatible renal allograft.
  2. Evidence of anti-HLA antibody (donor specific with an MFI >1000) as assessed by routine methodology (Luminex)
  3. Previous history of biopsy proven rejection.
  4. Persistent Leukopenia (WBC less than 2,000/mm3) or thrombocytopenia (\<100,000/mm3).
  5. Seropositivity for HIV-1, surface or core antigen, or hepatitis C virus (confirmed by hepatitis C virus RNA).
  6. Active infection
  7. \< 40% as determined by TTE or clinical evidence of heart failure.
  8. Forced expiratory volume or DLCO \< 50% of predicted.
  9. Lactation or pregnancy.
  10. History of cancer (following the American Transplant Society Guidelines)
  11. Underlying renal disease etiology with high risk of disease recurrence in the transplanted kidney (such as focal segmental glomerulosclerosis). diseases such as Lupus and Thrombotic Thrombocytopenic Purpura.
  12. Enrollment in other drug studies within 30 days prior to enrollment.
  13. Abnormal (>2 times lab normal) values for (a) liver function chemistries (, AST, AP), (b) , (c) coagulation studies (PT, ), or any patients on chronic anticoagulation therapy.
  14. Allergy or sensitivity to any component of Siplizumab, fludarabine, CP, tacrolimus, MMF or rituximab.
  15. Any medical condition that the investigator deems incompatible with participation in the trial. This includes a history of alcohol abuse or illicit drug use/dependence.
  16. Non-insulin dependent diabetes (NIDDM) without good blood glucose control (\<7). Severe retinopathy, gastroparesis, or severe neuropathy which prevent subject's normal independent daily activities.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Kidney and Stem Cell Recipients

    Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)

    Other: Bone Marrow Transplant · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Rituximab · Drug: Siplizumab

  • Experimental
    Kidney and Stem Cell Donors

    PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed

    Procedure: Peripheral Blood Stem Cell Collection

Interventions

  • OtherBone Marrow Transplant

    Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)

  • ProcedurePeripheral Blood Stem Cell Collection

    PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.

  • Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)

  • Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4

  • Rituximab on study day -6

  • Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.

06

What researchers measure

Primary outcomes

  1. Incidence of transient mixed chimerism

    Time frame: 3 months

  2. Incidence of renal allograft tolerance

    Time frame: 2 years after immunosuppression withdrawal

Secondary outcomes

  1. Incidence of Participant Survival

    Time frame: 2 years after immunosuppression withdrawal

  2. Incidence of Graft Survival

    Time frame: 2 years after immunosuppression withdrawal

  3. Incidence of Chimeric Transition Syndrome

    Time frame: 3 months

  4. Incidence of Allograft Rejection

    Measuring incidence of acute or chronic rejection free survival

    Time frame: 2 years after immunosuppression withdrawal

  5. Incidence of DSA

    Time frame: 2 years after immunosuppression withdrawal

  6. Incidence of GvHD

    Time frame: 2 years after immunosuppression withdrawal

  7. Incidence of infections

    Clinically significant, invasive or resistant opportunistic infection

    Time frame: 2 years after immunosuppression withdrawal

  8. Incidence of thymic irradiation toxicities

    Time frame: 2 years after immunosuppression withdrawal

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2023 (actual). Primary completion is estimated for Dec 2031, 98 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Dec 2028 → Dec 2031 and completion Dec 2030 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2023
First posted
Jun 12, 2023
StartActual
Oct 1, 2023
Primary completionEst.
Dec 2031was Dec 2028
CompletionEst.
Dec 2032was Dec 2030
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Sep 28, 2026
Sites
Massachusetts General Hospital is now Recruiting
Sep 28, 2026
Primary completion
Dec 2028→Dec 2031
Sep 28, 2026
Study completion
Dec 2030→Dec 2032
Sep 28, 2026
Contact
Study contact now listed: added t•••@mgh.harvard.edu · •••0289; added g•••@mgh.harvard.edu. See the current contact
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Massachusetts General Hospital · Boston, United StatesContact added t•••@mgh.harvard.edu · •••0289Contact added (no phone or email listed)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Active, not recruiting→Recruiting
    Massachusetts General Hospital is now Recruiting
    Primary completion Dec 2028→Dec 2031
    Study completion Dec 2030→Dec 2032
    Contact Study contact now listed: added t•••@mgh.harvard.edu · •••0289; added g•••@mgh.harvard.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Massachusetts General Hospital · Boston, United StatesContact added t•••@mgh.harvard.edu · •••0289Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05900401
Collaborators
Ossium Health, Inc., ITB-Med LLC
Responsible party
Tatsuo Kawai, MD, PhD (MD, PhD -- Professor of Surgery, Harvard Medical School, Massachusetts General Hospital) — Principal investigator
First posted
Jun 12, 2023
Start date
Oct 1, 2023
Primary completion
Dec 2031 (estimated)
Completion
Dec 2032 (estimated)
Last update
Sep 28, 2026

Study contacts

Tatsuo Kawai
Contact
tkawai@mgh.harvard.edu
617-726-0289
Gabriel Impreso Baysa
Contact
gimpresobaysa@mgh.harvard.edu
Tatsuo Kawai
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Cyclophosphamide · Rituximab · Siplizumab

Start the discussion